If you select the IPO category on the drop-down box here at LifeScienceDealFlow.com one can observe the tracking of the 2009 life science initial public offering story play out – you may also note perhaps a slight bias too, that is solely coverage of the US public markets have been delivered to date. Now Belgium-based [...]

• 634http://clsdf.com/2009/11/movetis-what%e2%80%99s-a-blog-to-do/Movetis+%7C+What%E2%80%99s+a+Blog+to+Do%3F2009-11-23+17%3A18%3A40admin

San Diego, CA-based Trius Therapeutics is looking to potentially represent the eighth biopharma IPO of the year if they are able to get out in the next month or so. With five companies trading (see matrix below), Trius is queued up alongside Anthera Pharma and Aldagen in an effort to make their Wall St. debut.

Taking [...]

• 623http://clsdf.com/2009/11/trius-therapeutics-5-out-3rd-in-the-ipo-queue/Trius+Therapeutics+%7C+5+Out%2C+3rd+in+the+IPO+Queue2009-11-19+01%3A03%3A05admin

And the 2009 IPO class grows with the announced filing of Durham, NC-based Aldagen. The post title is a poor attempt at a double entendre – the Company had previously filed their S-1 for a planned public offering approximately 12 months ago (updated filing is [HERE]), and their business model focuses on regenerative cell therapies, [...]

• 601http://clsdf.com/2009/11/aldagen-regenerative-ipo-filing/Aldagen+%7C+Regenerative+IPO+Filing2009-11-03+15%3A38%3A07admin

The mere fact that Burrill & WR Hambrecht are touting their team-up to focus on bringing life science companies to the public markets is certainly big news. A savvy salt & pepper life science CEO (who orchestrated a >$1B M&A of his small cap clinical-stage entity) turned managing partner of a Sand Hill Rd. [...]

• 585http://clsdf.com/2009/11/2010-impending-bio-ipo-pandemonium-part-2/2010+%7C+Impending+Bio+IPO+Pandemonium%21+Part+%2322009-11-02+02%3A37%3A05admin

2009 unambiguously marked a thawing of the bio IPO market – who froze up at the tail end of 2007 – by featuring six offerings, and a seventh filed that may still travel along the neon lights of the midtown Manhattan Nasdaq ticker before we see Dick Clark and friends ring in 2010 from just [...]

• 566http://clsdf.com/2009/10/2010-impending-bio-ipo-pandemonium-part-1/2010+%7C+Impending+Bio+IPO+Pandemonium%21+%28Part+%231%292009-10-31+04%3A55%3A08admin

We recently reported on the AGA Medical (NASDAQ: AGAM) – developer of interventional devices for the minimally invasive treatment of structural heart defects and peripheral vascular disorders – public filing intentions and can now follow-up with their initial public offering debut details and as well check in with AGA’s Bio IPO class of 2009 brethren. [...]

• 546http://clsdf.com/2009/10/aga-medical-bang-off-and-running%e2%80%a6/AGA+Medical+%7C+BANG%21+Off+and+Running%E2%80%A6+2009-10-27+14%3A35%3A13admin

Omeros (NASDAQ: OMER) launched itself onto the Nasdaq global marketplace yesterday with its initial public offering of 6.82M shrs priced at $10 raising approximately $68M less underwriting expenses. Its foray however, was more dud then thud relative to its peers in the Biopharma IPO Class of 2009. For Omeros is the only clinical-stage, pre-commercial, pre-revenue [...]

• 456http://clsdf.com/2009/10/omeros-lackluster-ipo-debut-a-good-sign/Omeros+%7C+Lackluster+IPO+Debut+a+Good+Sign%3F2009-10-09+13%3A38%3A00admin

AGA Medical (Plymouth, MN) developer of interventional devices for the minimally invasive treatment of structural heart defects and peripheral vascular disorders, first filed with the intention to reach the public market in 2008 (‘nuff said), now on the heels of what is shaping up to be, dare one say, an active 2H09 life science IPO [...]

• 455http://clsdf.com/2009/10/aga-medical-holdings-back-in-the-queue/AGA+Medical+Holdings+%7C+Back+in+the+Queue2009-10-08+14%3A15%3A00admin

Part of the [C]LSDF ongoing series Watching the Bio IPO Market.
Talecris Biotherapeutics (NASDAQ: TLCR) made a thunderous debut with its Initial Public Offering on the Nasdaq today, offering 50,000,000 shares at $19 and raising $950M in the process. The fun however, did not stop there as the third life science offering of the year powered [...]

• 449http://clsdf.com/2009/10/talecris-and-then-there-were-three/Talecris+%7C+And+Then+There+Were+Three%212009-10-02+02%3A06%3A00admin

CLSDF continues to maintain keen watch on the thawing of the public equity markets, calibrated in a semi-quantitative approach via the life science IPO pricings. If all three of the current filings get out priced ‘as-is’ I would then call the score FINANCING EVENT 3 & LIQUIDITY OPPORTUNITY 2. A nice balance and it makes [...]

• 442http://clsdf.com/2009/09/anthera-working-to-thaw-the-markets/Anthera+%7C+Working+to+Thaw+the+Markets2009-09-23+05%3A48%3A00admin

UPDATE: Lots can happen between an early morning blog post and the end of the business day. In this case Omeros has set its IPO terms; 6.82M common shares offered between $10 and $12 per share. So the company is hoping to raise between $68.2 and $81.8M. The planned ticker to trade under [...]

• 436http://clsdf.com/2009/09/1-ipo-2-ipo-3-ipo/1+IPO%21+2+IPO%3F%3F+3+IPO%3F%3F%3F2009-09-16+14%3A21%3A00admin